FundingWatcher
Home / Startups / By venture fund / EQT Life Sciences portfolio companies

EQT Life Sciences portfolio companies

Updated 16 Nov 2026

https://www.lspvc.com

EQT Life Sciences portfolio companies
One-time CSV
  • 23 funded companies, 20 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-life-sciences-partners.csv23 rows × 18 columns
CompanyCityLast roundAmountDate
Vico TherapeuticsLeidenSeries B$12.3M2024-06-24
PanTeraMolSeries A$110.3M2024-09-11
Shinobi TherapeuticsSouth San FranciscoSeries A$68.0M2024-08-06
VectorYAmsterdamSeries A$138.0M2023-11-13
Onera HealthEindhovenSeries C$32.6M2024-01-16
FoRx TherapeuticsBaselSeries A$50.0M2025-12-18
Binx HealthBostonSeries F$65.0M2024-04-02
Cardior PharmaceuticalsHanoverSeries B$75.3M2021-08-25

8 rows of the CSV in 5 of its 18 columns.

23
Startups
$1.6B
Total raised
1
Funded in the last 12 months
$50.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

17 of 23
17 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
SNIPR Biome SNIPR Biome develops discovery-stage biotech treatments for microbial diseases. Biotech Copenhagen, Denmark Series B $40.9M 2025-08-07 $103.4M Wellington Partners, Bill & Melinda Gates Foundation, EQT Life Sciences +1 11 to 50 2017
PanTera PanTera produces actinium-225 for personalized cancer treatment and radiopharmaceuticals. Health care Mol, Belgium Series A $110.3M 2024-09-11 Eurazeo, PMV, EQT Life Sciences +2 11 to 50 2022
Shinobi Therapeutics Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment. Biotech South San Francisco, United States Series A $68.0M 2024-08-06 $178.0M Mitsubishi UFJ Capital, F-Prime, EQT Life Sciences +2 11 to 50 2023
Asceneuron Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. Biotech Lausanne, Switzerland Series C $100.0M 2024-07-16 OrbiMed, Novo Holdings, EQT Life Sciences +1 1 to 10 2012
Vico Therapeutics Vico Therapeutics develops RNA modulating therapies. Biotech Leiden, The Netherlands Series B $12.3M 2024-06-24 $115.4M Polaris Partners, Eurazeo, EQT Life Sciences +2 11 to 50 2019
Phagenesis Phagenesis develops a device that treats dysphagia, a condition that makes swallowing food unsafe. Biotech Manchester, United Kingdom Series D $42.0M 2024-03-04 $71.4M MedTech Innovator, EQT Life Sciences, Northern Gritstone +2 11 to 50 2007
Onera Health Onera Health provides sleep diagnostics and monitoring products for clinical and home use. Hardware Eindhoven, The Netherlands Series C $32.6M 2024-01-16 $57.0M European Innovation Council, EQT Life Sciences, Gimv +1 11 to 50 2017
LUMA Vision LUMA Vision develops 4D cardiac imaging and navigation technology for point-of-therapy data delivery. Health care Harold's Cross, Ireland Series A $21.8M 2023-12-18 $54.0M Enterprise Ireland, European Innovation Council, Bayern Kapital +2 51 to 100 2017
VectorY VectorY develops gene therapies for central nervous system, somatic, and muscle diseases. Biotech Amsterdam, The Netherlands Series A $138.0M 2023-11-13 $175.6M Insight Partners, Benhamou Global Ventures, Forbion Capital Partners +2 51 to 100 2020
Cardior Pharmaceuticals Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. Biotech Hanover, Germany Series B $75.3M 2021-08-25 HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 11 to 50 2016
Arvelle Therapeutics Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. Biotech Basel, Switzerland Series A $42.7M 2020-05-27 KB Investment, F-Prime, EQT Life Sciences +2 51 to 100 2019
Endotronix Endotronix develops hemodynamic monitoring technologies that detect worsening heart failure earlier. Biotech Lisle, United States Series D $70.0M 2018-09-14 $129.6M Silicon Valley Bank, JumpStart Inc., EQT Life Sciences +1 101 to 250 2007
Luxendo Luxendo develops and manufactures proprietary light-sheet fluorescence microscopy instruments. Biotech Heidelberg, Germany Series A $8.5M 2017-01-12 EQT Life Sciences, EMBL Ventures, LSP BioVentures 11 to 50 2015
Okairos Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. Biotech Basel, Switzerland Series B $20.5M 2010-09-14 $30.1M EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 1 to 10 2007
Vivendy Therapeutics Vivendy Therapeutics develops enzyme replacement therapies. Biotech Basel, Switzerland Series B $30.5M 2008-06-23 EQT Life Sciences, BioMedPartners, TVM Capital +1 11 to 50 2006
4-Antibody AG 4-Antibody AG develops a human antibody drug-discovery platform for immuno-oncology therapeutics. Biotech Basel, Switzerland Series A $18.4M 2007-01-16 $20.6M EQT Life Sciences, BioMedPartners, Grazia Equity +2 251 to 500 2002

Table 1. EQT Life Sciences portfolio companies: the 17 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 23.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019

Table 2. EQT Life Sciences portfolio companies: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Andera Partners Private equity firm Paris, France 4 17%
2 Novartis Venture Fund Corporate venture arm Basel, Switzerland 3 13% 1 FoRx Therapeutics
3 BioMedPartners Venture capital firm Basel, Switzerland 3 13%
4 Eurazeo Private equity firm Paris, France 2 9%
5 Kurma Partners Venture capital firm Paris, France 2 9%
6 F-Prime Venture capital firm Cambridge, United States 2 9%
7 European Innovation Council Startup accelerator Brussels, Belgium 2 9%
8 OrbiMed Private equity firm New York, United States 2 9%
9 Boehringer Ingelheim Venture Fund Corporate venture arm Ingelheim Am Rhein, Germany 2 9%
10 Inkef Venture capital firm Amsterdam, The Netherlands 2 9%
11 Versant Ventures Venture capital firm Menlo Park, United States 2 9%
12 Novo Holdings Corporate venture arm Hellerup, Denmark 2 9%
13 Bayern Kapital Venture capital firm Landshut, Germany 2 9%
14 Sectoral Asset Management Private equity firm Montréal, Canada 2 9%
15 Wellington Partners Venture capital firm Munich, Germany 2 9%

Table 3. EQT Life Sciences portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 19 83% $1.5B
Biotech 18 78% $1.1B
Software 3 13% $283.4M
Hardware 2 9% $186.6M

Table 4. EQT Life Sciences portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 9 39% $42.7M
Series B 7 30% $30.5M
Series C 3 13% $32.6M
Series D+ 4 17% $65.0M

Table 5. EQT Life Sciences portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Switzerland 6 26%
Germany 6 26%
United States 4 17%
The Netherlands 3 13%
Belgium 1 4%
Ireland 1 4%
United Kingdom 1 4%
Denmark 1 4%

Table 6. EQT Life Sciences portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 5 22%
Berlin 2 9%
Leiden 1 4%
Mol 1 4%
South San Francisco 1 4%
Amsterdam 1 4%
Eindhoven 1 4%
Boston 1 4%
Hanover 1 4%
Lausanne 1 4%
Harold's Cross 1 4%
Manchester 1 4%

Table 7. EQT Life Sciences portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
December 2025 1 100% $50.0M

Table 8. EQT Life Sciences portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2025 2 9% $90.9M
2024 7 30% $430.3M
2023 3 13% $184.9M
2021 2 9% $185.3M
2020 1 4% $42.7M
2018 2 9% $90.0M

Table 9. EQT Life Sciences portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 4%
2020 to 2022 3 13%
2015 to 2019 9 39%
2010 to 2014 3 13%
Before 2010 7 30%

Table 10. EQT Life Sciences portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 2 9%
11 to 50 14 61%
51 to 100 5 22%
101 to 250 1 4%
251 to 500 1 4%

Table 11. EQT Life Sciences portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many EQT Life Sciences portfolio companies are on the list?
23, in the file dated 16 November 2026. 1 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 23 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

EQT Life Sciences portfolio companies: 23 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 23 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/life-sciences-partners/